Ligand Pharmaceuticals | LGND - Sales Revenues


Ligand Pharmaceuticals reported $83.7M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Agenus USD 33.7M 500K Mar/2026
Amgen USD 10.1B 1.48B Jun/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 75.23M 1.49M Jun/2026
Baxter International USD 2.96B 260M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Eli Lilly USD 22.97B 3.17B Jun/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Enviri Corporation USD 555M 19.81M Dec/2025
Gilead Sciences USD 7.8B 800M Jun/2026
GlaxoSmithKline GBP 8.41B 781M Jun/2026
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 425.49M 119.53M Jun/2026
Intrexon USD 717K 511K Jun/2024
Ionis Pharmaceuticals USD 268M 22M Jun/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Ligand Pharmaceuticals USD 83.7M 31.98M Jun/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Merck USD 16.6B 310M Jun/2026
Pacira USD 192.4M 15.4M Jun/2026
Pfizer USD 15.03B 530M Jun/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Veracyte USD 150.32M 11.25M Jun/2026